Panacea Biotec bags PAHO vaccine supply order worth USD 4.75M

Export Order Hard CurrencyBusiness Updates View source PDF Explain this filing

PANACEABIO · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.5%Reaction day

₹397.90

prior close

₹402.40

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+0.9%-0.4% vs market

Pharmaceuticals peers, median of 157sector+0.8%-0.3% vs sector

On the reaction day the stock moved 0.4 pts less than Nifty Microcap 250 and 0.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.6

10m

-0.6

15m

-0.6

30m

-0.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.5+0.9-0.4+0.8-0.3

Next day

+2.0+0.8+1.2+0.5+1.6

+0.2+0.7-0.6+0.4-0.2

-1.8+1.3-3.2+0.6-2.4

-6.0+0.5-6.5-0.1-5.9

-8.2+0.4-8.6-0.6-7.7

-13.3-1.5-11.8-1.2-12.1

15d

-11.8-2.4-9.4-1.8-10.0

-8.8-4.4-4.4-2.6-6.2

+1.3-7.2+8.5-5.4+6.7

-10.1-5.0-5.1-5.7-4.4

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 157Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Panacea Biotec received an award notification from PAHO for supplying Easyfive-TT pentavalent vaccine worth about US$ 4.75 million (around Rs. 41 crore) for Calendar Year 2026 and 2027. The order is under a Long-Term Agreement valid until December 31, 2027, and is international in nature. PAHO is WHO's regional office for the Americas.

Likely market impact

Positive export order in US dollars from international health body, adding to revenue visibility over the next two years.